Issue Contents

From Basic Immunology to Clinical Practice: Bio-Originators versus Bio-Similars

Stamatis-Nick C. Liossis, Georgia M. Konstantopoulou

Mediterr J Rheumatol 2019;30(Supp 1):54-8
SB4 in the Era of Biosimilars: Clinical Data and Real-World Experience

Shing T. Law, Peter C. Taylor

Mediterr J Rheumatol 2019;30(Supp 1):59-62
The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice

Evrydiki Kravvariti, George D. Kitas, Petros P. Sfikakis

Mediterr J Rheumatol 2019;30(Supp 1):63-8
Switching patients with inflammatory arthritis from Etanercept (Enbrel) to the biosimilar drug, SB4 (Benepali): A single-centre retrospective observational study in the UK and a review of the literature

Anastasia-Vasiliki Madenidou, Andrew Jeffries, Sneha Varughese, Stephen Jones, Hanadi Sari-Kouzel, Helen Veevers, Chandini Rao

Mediterr J Rheumatol 2019;30(Supp 1):69-75
Biosimilars in the management of chronic inflammatory diseases: The Dutch experience

Wieland D. Müskens, Sanne A. A. Rongen-van Dartel, Eddy M. M. Adang, Piet L. C. M. van Riel

Mediterr J Rheumatol 2019;30(Supp 1):76-81
2018 Position Paper on Biosimilars of the Greek Rheumatology Society and Professional Association of Greek Rheumatologists

Dimos Patrikos, Kyriaki Boki, Dimitrios Boumpas, Dimitrios Vassilopoulos

Mediterr J Rheumatol 2019;30(Supp 1):82-3

ARCHIVE